Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology

Area of Science:

• Immunology
• Oncology
• Structural Biology

Background:

• Cancer cells evade immune surveillance via immune checkpoint proteins such as programmed death 1 (PD-1), PD-L1, and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
• FDA-approved antibody drugs targeting these checkpoints have yielded significant breakthroughs in treating diverse cancers, inducing durable responses.

Purpose of the Study:

• To review recent structural studies of monoclonal antibodies targeting PD-1, PD-L1, and CTLA-4.
• To analyze the interactions between these antibodies and immune checkpoint proteins.
• To provide a foundation for designing next-generation immuno-oncology therapies.

Main Methods:

• Review of published crystal structures of antibodies against PD-1, PD-L1, and CTLA-4.
• Analysis of molecular interactions between therapeutic antibodies and their target immune checkpoint proteins.

Main Results:

• Recent crystal structures illuminate the binding interfaces of antibodies with PD-1, PD-L1, and CTLA-4.
• Understanding these interactions is crucial for elucidating therapeutic mechanisms of action.

Conclusions:

• Structural insights into immune checkpoint inhibitors enhance comprehension of their efficacy.
• Accumulated structural data are essential for the rational design of novel immuno-oncology treatments.